Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Genetic screening for important variants in breast cancer patients under 60 years

Felipe Batalini, MD, Beth Israel Deaconess Medical Center, Boston, MA, expresses the current complex screening process to determine which women with breast cancer should undergo genetic testing and how this can have significant implications for the cancer patient themselves and their families. Consistent with National Comprehensive Cancer Network (NCCN) criteria, simplifying the selection process by screening all women with breast cancer ≤60 years of age and retaining the more complex criteria for breast cancer patients over the age of 60 may reduce the incidence of undetected and significant genetic variants in breast cancer patients. This interview was conducted at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.